Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European cooperative study of primary systemic therapy in operable breast cancer <2 cm
2004-004957-24Phase 2Completed
- Sponsor
- Michelangelo Foundation
- Start
- Jul 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of capecitabine, doxorubicin, cyclophosphamide, methotrexate, fluorouracil and 2 more in breast cancer, sponsored by Michelangelo Foundation. Started Jul 2005; status: completed.
02
Drugs
capecitabinedoxorubicincyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-004957-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004957-24.